{"id":"metformin-0-85-twice-daily-for-6-months","safety":{"commonSideEffects":[{"rate":"20–30","effect":"Gastrointestinal disturbance (nausea, diarrhea, abdominal discomfort)"},{"rate":"3–5","effect":"Metallic taste"},{"rate":"10–30","effect":"Vitamin B12 deficiency"},{"rate":"<0.1","effect":"Lactic acidosis (rare, in renal impairment)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Metformin is a biguanide that primarily works by decreasing gluconeogenesis in the liver and enhancing glucose uptake and utilization in muscle and adipose tissue. It may also improve insulin secretion from pancreatic beta cells and reduce intestinal glucose absorption. The drug does not stimulate insulin release, making hypoglycemia unlikely when used as monotherapy.","oneSentence":"Metformin reduces hepatic glucose production and improves insulin sensitivity in peripheral tissues, lowering blood glucose levels in type 2 diabetes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:54:38.876Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT02745886","phase":"PHASE4","title":"Metformin Induces a Dietary Restriction-like State in Human","status":"UNKNOWN","sponsor":"Xiang Guang-da","startDate":"2016-04","conditions":"Overweight Subjects, Metformin, Aging","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"metformin 0.85 twice daily for 6 months","genericName":"metformin 0.85 twice daily for 6 months","companyName":"Xiang Guang-da","companyId":"xiang-guang-da","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Metformin reduces hepatic glucose production and improves insulin sensitivity in peripheral tissues, lowering blood glucose levels in type 2 diabetes. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}